Literature DB >> 8822355

Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction.

T Maurice1, B P Lockhart, A Privat.   

Abstract

Substantial evidences suggest that the increased cerebral deposition, and neurotoxic action of the beta-amyloid peptide, the major constituent of senile plaques, may represent the underlying cause of the cognitive deficits observed in Alzheimer's disease. Herein, we attempted to verify this hypothesis by inducing a potential Alzheimer's-type amnesia after direct intracerebroventricular administration of aggregated beta 25-35-amyloid peptide in mice. In this aim, mnesic capacities were evaluated after 6-13 days, using spontaneous alternation in the Y-maze, step-down type passive avoidance and place learning in a water-maze. Pretraining administration of aggregated beta 25-35 peptide induced dose-dependent decreases in both alternation behaviour and passive avoidance, at doses of 3 and 9 nmol/mouse. A reduced but still significant impairment was observed when the peptide was not aggregated, or 'aged', by preincubation for 4 days at 37 degrees C. The beta 1-28 peptide, at 3 nmol/mouse, also induced a marked decrease in step-down latency. Posttraining, but not preretention, administration of beta 25-35 peptide also significantly impaired learning. The beneficial effects of cholinergic agents on beta 25-35-induced amnesia was examined using the cholinesterase inhibitor tacrine (THA, 1.3 and 4.3 mumol/kg i.p.) and the nicotinic receptor agonist (-)-nicotine (NIC, 0.06 and 0.2 mumol/kg i.p.). Both drugs induced a dose-dependent abrogation of the beta 25-35-induced decreases in alternation behaviour and passive avoidance. Furthermore, THA, at 1.3 mumol/kg, and NIC, at 0.2 mumol/kg, also reversed the beta 25-35-induced impairment of place learning and retention in the water-maze. Histological examination of Cresyl violet-stained brain sections indicated a moderate but significant cell loss within the frontoparietal cortex and the hippocampal formation of mice treated with aged beta 25-35 peptide (9 nmol). Examination of Congo red-stained sections in the same animals demonstrated the presence of numerous amyloid deposits throughout these brain areas. These results confirm that the deposition of beta-amyloid peptide in the brain is in some way related to impairment of learning and cholinergic degeneration and suggest that the [25-35] fragment of the beta-amyloid protein, sufficient to induce neuronal death in cultures, also induces an Alzheimer's-type amnesia in mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822355     DOI: 10.1016/0006-8993(95)01032-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  127 in total

1.  Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation.

Authors:  L Lin; B Georgievska; A Mattsson; O Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Administration of aggregated beta-amyloid peptide (25-35) induces changes in long-term potentiation in the hippocampus in vivo.

Authors:  V V Trubetskaya; M Yu Stepanichev; M V Onufriev; N A Lazareva; V A Markevich; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2003-02

3.  cDNA microarray analysis of gene expression in the cerebral cortex and hippocampus of BALB/c mice subjected to chronic mild stress.

Authors:  Yanyong Liu; Nan Yang; Pingping Zuo
Journal:  Cell Mol Neurobiol       Date:  2010-06-09       Impact factor: 5.046

4.  Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.

Authors:  Yu-Fang Cheng; Chuang Wang; Huan-Bing Lin; Yun-Feng Li; Ying Huang; Jiang-Ping Xu; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2010-07-17       Impact factor: 4.530

5.  Ilex latifolia Prevents Amyloid β Protein (25-35)-Induced Memory Impairment by Inhibiting Apoptosis and Tau Phosphorylation in Mice.

Authors:  Joo Youn Kim; Hong Kyu Lee; Ji Yeon Jang; Jae Kuk Yoo; Yeon Hee Seong
Journal:  J Med Food       Date:  2015-08-20       Impact factor: 2.786

6.  Studies of the effects of fragment (25-35) of beta-amyloid peptide on the behavior of rats in a radial maze.

Authors:  M Yu Stepanichev; Yu V Moiseeva; N A Lazareva; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2005-06

7.  Anti-amnesic effect of dimemorfan in mice.

Authors:  Hui-Hung Wang; Jyh-Wei Chien; Yueh-Ching Chou; Jyh-Fei Liao; Chieh-Fu Chen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  The modulatory role of phloretin in Aβ25-35 induced sporadic Alzheimer's disease in rat model.

Authors:  Priya J Ghumatkar; Sachin P Patil; Vaibhavi Peshattiwar; Tushara Vijaykumar; Vikas Dighe; Geeta Vanage; Sadhana Sathaye
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-11-28       Impact factor: 3.000

9.  Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling.

Authors:  Ottavio V Vitolo; Antonino Sant'Angelo; Vincenzo Costanzo; Fortunato Battaglia; Ottavio Arancio; Michael Shelanski
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-20       Impact factor: 11.205

10.  Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

Authors:  Valentine Lahmy; Johann Meunier; Susanna Malmström; Gaelle Naert; Laurent Givalois; Seung Hyun Kim; Vanessa Villard; Alexandre Vamvakides; Tangui Maurice
Journal:  Neuropsychopharmacology       Date:  2013-03-14       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.